drugset
drugset / Trial / NCT02713945

Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome

NCT02713945 ↗

Phase 3 Completed 53 enrolled University Hospital, Toulouse
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluate the efficacy of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors, also known as "statins" in the treatment of growth and skeletal abnormalities in children with Noonan syndrome. Half of patients will receive simvastatin while the other half will receive a placebo.

Timeline

Start
2017-01-25
Primary completion
2023-03-03
Completion
2023-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 20 mg Oral
Subject Simvastatin Small molecule 40 mg Oral

Indications

Noonan syndrome